Montreal, PQ- February 9, 2000 – Paladin Labs Inc. (“Paladin”) (TSE: PLB) today announced that the Therapeutic Products Programme (“TPP”) has granted Plan B^TM a notice of compliance permitting the sale of Plan B^TM in Canada.

In December 1999, Paladin acquired the exclusive Canadian distribution rights for Plan B^TM from the Women’s Capital Corporation (“WCC”). Plan B^TM is the first levonorgestrel-only post-coital contraceptive approved by the TPP & the U.S. Food & Drug Administration.

Dr. Sharon Camp, President of WCC and long-time activist for women’s health, says “the approval of Plan B^TM in Canada marks an important advance in reproductive health-care for women. According to clinical data published in the Lancet (August 8, 1999) and our FDA-approved labeling, Plan B^TM demonstrated a superior safety profile (less nausea and vomiting) over the 25-year old Yuzpe regimen, which was recently approved in Canada. Plan B^TM is not effective if a woman is already pregnant and will not terminate an existing pregnancy.”

Mr. Jonathan Goodman, President & CEO of Paladin stated “Based upon its superior side-effect profile over currently approved products in Canada, we believe that Plan B^TM will become the emergency-contraceptive of choice for Canadian women. We are privileged to be associated with the WCC and their quest to develop superior health products for women such as Plan B^TM. We intend to launch Plan B during the 2^nd Quarter of 2000.”

 

About Paladin Labs Inc.

Paladin Labs, headquartered in Montreal, Quebec is a Canadian developer, marketer and distributor of innovative pharmaceuticals, currently offering products in urology, dermatology, rheumatology and other specialty markets. For more information about Paladin, please visit the Paladin Web Site at www.paladin-labs.com or send e-mail to info@paladin-labs.com.

Paladin Labs Inc. is a public company whose shares trade on the Toronto Stock Exchange and the Canadian Venture Exchange under the symbol PLB.

PALADIN LABS INC.

          The Canadian Venture Exchange & the Toronto Stock Exchange have not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements or predictions. These statements represent our judgement as of this date and are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed in such forward-looking statements. Potential risks and uncertainties include, without limitation, those associated with product development, clinical trials, future revenues and profitability, and obtaining marketing approval.

About Women’s Capital Corporation

The Women’s Capital Corporation is a privately held company organized to bring Plan B^TM to the U.S and Canadian markets and to develop other critically needed reproductive health products for women. Financing for Plan B^TM has come, in large part, from U.S. foundations and from several local Planned Parenthood organizations that have made an equity investment in WCC. For more information about WCC, please visit the Plan B^TM Web Site at www.go2planB.com, send e-mail to info@thewcc.com, or call 800-330-1271.

 

For more information:

For Information about Plan BTM:

Lennie Ryer, C.A., CFE Chief Financial Officer Paladin Labs Inc. Tel: 514-340-5067 e-mail: lryer@paladin-labs.com Web Site: www.paladin-labs.com

Pamela Long DDB New York 212 415 2099 Arlene Fairfield DDB Seattle 206 223 6309